Related Experiment Video
Updated: May 27, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
The cell cycle regulator CDC25A is a target for JAK2V617F oncogene
Emilie-Fleur Gautier1, Muriel Picard, Camille Laurent
1INSERM UMR 1037-Cancer Research Center of Toulouse, Université de Toulouse, Centre Hospitalier Universitaire Purpan, Toulouse, France.
Blood
|November 9, 2011
Summary
The JAK2(V617F) mutation drives overexpression of CDC25A phosphatase, a key cell cycle regulator. Inhibiting CDC25A reduces proliferation in JAK2-mutated cells, suggesting it as a therapeutic target for myeloproliferative neoplasms.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- The JAK2(V617F) mutation is a key driver in myeloproliferative neoplasms like polycythemia vera and essential thrombocythemia.
- This mutation leads to constitutive Janus kinase 2 (JAK2) signaling, contributing to disease pathogenesis.
- JAK2(V617F) is known to promote cell cycle progression, specifically entry into the S-phase.
Purpose of the Study:
- To investigate the role of CDC25A phosphatase in JAK2(V617F)-driven myeloproliferative neoplasms.
- To elucidate the regulatory mechanisms of CDC25A overexpression in the context of JAK2(V617F) mutation.
- To evaluate CDC25A as a potential therapeutic target in JAK2(V617F)-positive hematologic disorders.
Main Methods:
- Analysis of CDC25A expression in JAK2(V617F)-positive cell lines, patient progenitors, and murine models.
- Investigation of CDC25A regulation at transcriptional, post-transcriptional, and translational levels.
- Assessment of the effects of CDC25A inhibition on JAK2(V617F)-expressing cells and normal erythroid progenitors.
Main Results:
- Constitutive overexpression of CDC25A was observed in JAK2(V617F)-positive cells and progenitors, as well as in Jak2(V617F) knock-in mice.
- JAK2(V617F)-induced CDC25A upregulation is regulated at the translational level via STAT5 and eIF2α, not by increased transcription or stability.
- Inhibition of CDC25A significantly reduced the proliferation and clonogenic potential of JAK2(V617F)-expressing cells and erythroid progenitors.
Conclusions:
- CDC25A phosphatase is constitutively overexpressed in JAK2(V617F)-driven myeloproliferative conditions.
- Translational regulation by STAT5 and eIF2α is critical for CDC25A upregulation in JAK2(V617F) cells.
- CDC25A represents a promising therapeutic target for managing hematopoietic cell expansion in JAK2(V617F) patients.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
00:50Anaphase Promoting Complex
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...